Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control

  • Moyano, Ana
  • Blanch Lombarte, Oscar
  • Tarancón Diez, Laura
  • Pedreño Lopez, Nuria
  • Arenas Busto, Miguel
  • Alvaro, Tamara
  • Casado, Concepción
  • Olivares, Isabel
  • Vera, Mar
  • Rodríguez, Carmen
  • del Romero, Jorge
  • López Galíndez, Cecilio
  • Ruiz Mateos, Ezequiel
  • Prado, Julia G.
  • Pernas, María
Background Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs. Results In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC. Conclusions These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses., Instituto de Salud Carlos III | Ref. PI13/02269, Instituto de Salud Carlos III | Ref. PI17/00164, Instituto de Salud Carlos III | Ref. PI16/0684, Instituto de Salud Carlos III | Ref. PI19/01127, Ministerio de Economía y Competitividad | Ref. RD12/0017/0028, Ministerio de Economía y Competitividad | Ref. RD16/0025/0020, Generalitat de Catalunya | Ref. AGAUR-FI_B 00582, Agencia Estatal de Investigación | Ref. RYC-2015-18241, Agencia Estatal de Investigación | Ref. PID2019-107931GA-I00, Xunta de Galicia | Ref. ED431F 2018/08, Ministerio de Economía y Competitividad | Ref. RD16/0025/0041
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antigen production after latency reversal and expression of inhibitory receptors in CD8+ T cells limit the killing of HIV-1 reactivated cells

  • Ruiz, Alba
  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Ouchi, Dan|||0000-0002-8630-152X
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Peña, Ruth
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Goulder, Philip|||0000-0002-9842-4674
  • Barnard, Richard
  • Howell, Bonnie J.
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Prado, Julia G.|||0000-0002-5439-4645
The so-called shock and kill therapies aim to combine HIV-1 reactivation by latency-reversing agents (LRA) with immune clearance to purge the HIV-1 reservoir. The clinical use of LRA has demonstrated detectable perturbations in the HIV-1 reservoir without measurable reductions to date. Consequently, fundamental questions concerning the limitations of the recognition and killing of LRA-reactivated cells by effector cells such as CD8+ T cells remain to be answered. Here, we developed a novel experimental framework where we combine the use of cytotoxic CD8+ T-cell lines and ex vivo CD8+ T cells from HIV-1-infected individuals with functional assays of LRA-inducible reactivation to delineate immune barriers to clear the reservoir. Our results demonstrate the potential for early recognition and killing of reactivated cells by CD8+ T cells. However, the potency of LRAs when crossing the barrier for antigen presentation in target cells, together with the lack of expression of inhibitory receptors in CD8+ T cells, are critical events to maximize the speed of recognition and the magnitude of the killing of LRA-inducible provirus. Taken together, our findings highlight direct limitations in LRA potency and CD8+ T cell functional status to succeed in the cure of HIV-1 infection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection

  • Guillén, Yolanda|||0000-0001-8673-6470
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Rivera Pinto, Javier|||0000-0002-4427-6442
  • Casadellà, Maria|||0000-0002-4115-2305
  • Zevin, Alexander
  • Rocafort, M.
  • Parera, M.
  • Rodríguez Rügnitz, M. Cristina
  • Arumí Rovira, Marçal
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Estany Quera, Carla|||0000-0001-6993-5865
  • Coll, Josep
  • Bravo, Isabel
  • Herrero, Cristina
  • Saz, Jorge|||0000-0002-8679-634X
  • Sirera, Guillem|||0000-0003-4014-9355
  • Torrella Domingo, Adriana|||0000-0003-1848-5096
  • Navarro, Jordi|||0000-0002-7187-0367
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Brander, Christian|||0000-0002-0548-5778
  • Blanco, Julià|||0000-0002-2225-0217
  • Calle, M. Luz|||0000-0001-9334-415X
  • Klatt, N. R.
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Paredes, Roger|||0000-0002-6553-691X
Human immunodeficiency virus (HIV)-1 infection causes severe gut and systemic immune damage, but its effects on the gut microbiome remain unclear. Previous shotgun metagenomic studies in HIV-negative subjects linked low-microbial gene counts (LGC) to gut dysbiosis in diseases featuring intestinal inflammation. Using a similar approach in 156 subjects with different HIV-1 phenotypes, we found a strong, independent, dose-effect association between nadir CD4+ T-cell counts and LGC. As in other diseases involving intestinal inflammation, the gut microbiomes of subjects with LGC were enriched in gram-negative Bacteroides, acetogenic bacteria and Proteobacteria, which are able to metabolize reactive oxygen and nitrogen species; and were depleted in oxygen-sensitive methanogenic archaea and sulfate-reducing bacteria. Interestingly, subjects with LGC also showed increased butyrate levels in direct fecal measurements, consistent with enrichment in Roseburia intestinalis despite reductions in other butyrate producers. The microbiomes of subjects with LGC were also enriched in bacterial virulence factors, as well as in genes associated with beta-lactam, lincosamide, tetracycline, and macrolide resistance. Thus, low nadir CD4+ T-cell counts, rather than HIV-1 serostatus per se, predict the presence of gut dysbiosis in HIV-1 infected subjects. Such dysbiosis does not display obvious HIV-specific features; instead, it shares many similarities with other diseases featuring gut inflammation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evolution of the gut microbiome following acute HIV-1 infection

  • Rocafort, Muntsa|||0000-0002-2991-1444
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Rivera Pinto, Javier|||0000-0002-4427-6442
  • Pastor Palomo, Lucía|||0000-0002-8346-514X
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Langhorst, Jost
  • Parera, Mariona|||0000-0002-0756-8307
  • Mandomando, Inacio|||0000-0002-1078-2187
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Urrea, Víctor|||0000-0002-2577-856X
  • Rodríguez Rügnitz, M. Cristina
  • Casadellà, Maria|||0000-0002-4115-2305
  • Calle, M. Luz|||0000-0001-9334-415X
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Blanco, Julià|||0000-0002-2225-0217
  • Naniche, Denise|||0000-0002-4495-6325
  • Paredes, Roger|||0000-0002-6553-691X
In rhesus macaques, simian immunodeficiency virus infection is followed by expansion of enteric viruses but has a limited impact on the gut bacteriome. To understand the longitudinal effects of HIV-1 infection on the human gut microbiota, we prospectively followed 49 Mozambican subjects diagnosed with recent HIV-1 infection (RHI) and 54 HIV-1-negative controls for 9-18 months and compared them with 98 chronically HIV-1-infected subjects treated with antiretrovirals (n = 27) or not (n = 71). We show that RHI is followed by increased fecal adenovirus shedding, which persists during chronic HIV-1 infection and does not resolve with ART. Recent HIV-1 infection is also followed by transient non-HIV-specific changes in the gut bacterial richness and composition. Despite early resilience to change, an HIV-1-specific signature in the gut bacteriome-featuring depletion of Akkermansia, Anaerovibrio, Bifidobacterium, and Clostridium- previously associated with chronic inflammation, CD8+ T cell anergy, and metabolic disorders, can be eventually identified in chronically HIV-1-infected subjects. Recent HIV-1 infection is associated with increased fecal shedding of eukaryotic viruses, transient loss of bacterial taxonomic richness, and long-term reductions in microbial gene richness. An HIV-1-associated microbiome signature only becomes evident in chronically HIV-1-infected subjects. The online version of this article (10.1186/s40168-019-0687-5) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synonymous genome recoding, a tool to explore microbial biology and new therapeutic strategies

  • Martínez, Miguel Angel
  • Jordan de Paiz, Ana|||0000-0002-3495-7201
  • Franco Cirera, Sandra|||0000-0003-4126-2202
  • Nevot Banús, Maria|||0000-0003-4947-4648
Synthetic genome recoding is a new means of generating designed organisms with altered phenotypes. Synonymous mutations introduced into the protein coding region tolerate modifications in DNA or mRNA without modifying the encoded proteins. Synonymous genome-wide recoding has allowed the synthetic generation of different small-genome viruses with modified phenotypes and biological properties. Recently, a decreased cost of chemically synthesizing DNA and improved methods for assembling DNA fragments (e.g. lambda red recombination and CRISPR-based editing) have enabled the construction of an Escherichia coli variant with a 4-Mb synthetic synonymously recoded genome with a reduced number of sense codons (n = 59) encoding the 20 canonical amino acids. Synonymous genome recoding is increasing our knowledge of microbial interactions with innate immune responses, identifying functional genome structures, and strategically ameliorating cis-inhibitory signaling sequences related to splicing, replication (in eukaryotes), and complex microbe functions, unraveling the relevance of codon usage for the temporal regulation of gene expression and the microbe mutant spectrum and adaptability. New biotechnological and therapeutic applications of this methodology can easily be envisaged. In this review, we discuss how synonymous genome recoding may impact our knowledge of microbial biology and the development of new and better therapeutic methodologies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy

  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Santos, José Ramón|||0000-0002-0886-7114
  • Peña, Ruth
  • Jiménez Moyano, Esther
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Paredes, Roger|||0000-0002-6553-691X
  • Prado, Julia G.|||0000-0002-5439-4645
Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the development of resistance-associated mutations in the protease gene. From a cohort of 520 HIV-infected subjects treated with lopinavir/ritonavir or darunavir/ritonavir monotherapy, we retrospectively identified nine patients with VF. We sequenced the HIV-1 Gag-protease region and generated clonal virus from plasma samples. We characterized phenotypically clonal variants in terms of replicative capacity and susceptibility to PIs. Also, we used VESPA to identify signature mutations and 3D molecular modelling information to detect conformational changes in the Gag region. All subjects analysed harboured Gag-associated polymorphisms in the absence of resistance mutations in the protease gene. Most Gag changes occurred outside Gag cleavage sites. VESPA analyses identified K95R and R286K (P < 0.01) as signature mutations in Gag present at VF. In one out of four patients with clonal analysis available, we identified clonal variants with high replicative capacity and 8- to 13-fold reduction in darunavir susceptibility. These clonal variants harboured K95R, R286K and additional mutations in Gag. Low susceptibility to darunavir was dependent on the Gag sequence context. All other clonal variants analysed preserved drug susceptibility and virus replicative capacity. Gag mutations may reduce darunavir susceptibility in the absence of protease mutations while preserving viral fitness. This effect is Gag-sequence context dependent and may occur during boosted PI failure.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression

  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Urrea, Víctor|||0000-0002-2577-856X
  • Dalmau, Judith|||0000-0001-7513-3711
  • Lopez, Miguel
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Ouchi, Dan|||0000-0002-8630-152X
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Passaes, Caroline|||0000-0002-0813-2521
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
  • Saez-Cirion, Asier
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Esteller, M.|||0000-0003-4490-6093
  • Berdasco, Maria|||0000-0002-6750-0400
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
BACKGROUND: Human genetic variation-mostly in the human leukocyte antigen (HLA) and C-C chemokine receptor type 5 (CCR5) regions-explains 25% of the variability in progression of human immunodeficiency virus (HIV) infection. However, it is also known that viral infections can modify cellular DNA methylation patterns. Therefore, changes in the methylation of cytosine-guanine (CpG) islands might modulate progression of HIV infection. METHODS: In total, 85 samples were analyzed: 21 elite controllers (EC), 21 subjects with HIV before combination antiretroviral therapy (cART) (viremic, 93 325 human immunodeficiency virus type 1 [HIV-1] RNA copies/mL) and under suppressive cART (cART, median of 17 months, <50 HIV-1 RNA copies/mL), and 22 HIV-negative donors (HIVneg). We analyzed the methylation pattern of 485 577 CpG in DNA from peripheral CD4+ T lymphocytes. We selected the most differentially methylated gene (TNF) and analyzed its specific methylation, messenger RNA (mRNA) expression, and plasma protein levels in 5 individuals before and after initiation of cART. RESULTS: We observed 129 methylated CpG sites (associated with 43 gene promoters) for which statistically significant differences were recorded in viremic versus HIVneg, 162 CpG sites (55 gene promoters) in viremic versus cART, 441 CpG sites (163 gene promoters) in viremic versus EC, but none in EC versus HIVneg. The TNF promoter region was hypermethylated in viremic versus HIVneg, cART, and EC. Moreover, we observed greater plasma levels of TNF in viremic individuals than in EC, cART, and HIVneg. CONCLUSIONS: Our study shows that genome methylation patterns vary depending on HIV infection status and progression profile and that these variations might have an impact on controlling HIV infection in the absence of cART.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhancement of Antiviral CD8 + T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab

  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Revollo, Boris|||0000-0001-9245-2183
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Llibre Codina, Josep Maria|||0000-0002-7158-6753
  • Manzano, José Luís
  • Boada, Aram|||0000-0001-9809-5308
  • Dalmau, Judith|||0000-0001-7513-3711
  • E. Speiser, Daniel
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • G. Prado, Julia
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
Background: Pembrolizumab is an immune checkpoint inhibitor against programmed cell death protein-1 (PD-1) approved for therapy in metastatic melanoma. PD-1 expression is associated with a diminished functionality in HIV-1 specific-CD8 + T cells. It is thought that PD-1 blockade could contribute to reinvigorate antiviral immunity and reduce the HIV-1 reservoir. Methods: Upon metastatic melanoma diagnosis, an HIV-1-infected individual on stable suppressive antiretroviral regimen was treated with pembrolizumab. A PET-CT was performed before and one year after pembrolizumab initiation. We monitored changes in the immunophenotype and HIV-1 specific-CD8 + T-cell responses during 36 weeks of treatment. Furthermore, we assessed changes in the viral reservoir by total HIV-1 DNA, cell-associated HIV-1 RNA, and ultrasensitive plasma viral load. Results: Complete metabolic response was achieved after pembrolizumab treatment of metastatic melanoma. Activated CD8 + T-cells expressing HLA-DR + /CD38 + transiently increased over the first nine weeks of treatment. Concomitantly, there was an augmented response of HIV-1 specific-CD8 + T cells with TNF production and poly-functionality, transitioning from TNF to an IL-2 profile. Furthermore, a transient reduction of 24% and 32% in total HIV-1 DNA was observed at weeks 3 and 27, respectively, without changes in other markers of viral persistence. Conclusions: These data demonstrate that pembrolizumab may enhance the HIV-1 specific-CD8 + T-cell response, marginally affecting the HIV-1 reservoir. A transient increase of CD8 + T-cell activation, TNF production, and poly-functionality resulted from PD-1 blockade. However, the lack of sustained changes in the viral reservoir suggests that viral reactivation is needed concomitantly with HIV-1-specific immune enhancement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Restriction Factors, From Intrinsic Viral Restriction to Shaping Cellular Immunity Against HIV-1

  • Colomer-Lluch, Marta
  • Ruiz, Alba
  • Moris, Arnaud
  • Prado, Julia G.|||0000-0002-5439-4645
Antiviral restriction factors are host cellular proteins that constitute a first line of defense blocking viral replication and propagation. In addition to interfering at critical steps of the viral replication cycle, some restriction factors also act as innate sensors triggering innate responses against infections. Accumulating evidence suggests an additional role for restriction factors in promoting antiviral cellular immunity to combat viruses. Here, we review the recent progress in our understanding on how restriction factors, particularly APOBEC3G, SAMHD1, Tetherin, and TRIM5α have the cell-autonomous potential to induce cellular resistance against HIV-1 while promoting antiviral innate and adaptive immune responses. Also, we provide an overview of how these restriction factors may connect with protein degradation pathways to modulate anti-HIV-1 cellular immune responses, and we summarize the potential of restriction factors-based therapeutics. This review brings a global perspective on the influence of restrictions factors in intrinsic, innate, and also adaptive antiviral immunity opening up novel research avenues for therapeutic strategies in the fields of drug discovery, gene therapy, and vaccines to control viral infections.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors

  • Codoñer, Francisco M.
  • Peña, Ruth
  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Pino, Maria
  • Vollbrecht, Thomas
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Draenert, Rika
  • Prado, Julia G.|||0000-0002-5439-4645
Despite the major role of Gag in establishing resistance of HIV-1 to protease inhibitors (PIs), very limited data are available on the total contribution of Gag residues to resistance to PIs. To identify in detail Gag residues and structural interfaces associated with the development of HIV-1 resistance to PIs, we traced viral evolution under the pressure of PIs using Gag-protease single genome sequencing and coevolution analysis of protein sequences in 4 patients treated with PIs over a 9-year period. We identified a total of 38 Gag residues correlated with the protease, 32 of which were outside Gag cleavage sites. These residues were distributed in 23 Gag-protease groups of coevolution, with the viral matrix and the capsid represented in 87% and 52% of the groups. In addition, we uncovered the distribution of Gag correlated residues in specific protein surfaces of the inner face of the viral matrix and at the Cyclophilin A binding loop of the capsid. In summary, our findings suggest a tight interdependency between Gag structural proteins and the protease during the development of resistance of HIV-1 to PIs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control

  • Moyano, Ana
  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Tarancon-Diez, Laura
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Arenas, Miguel
  • Alvaro, Tamara
  • Casado, Concepcion
  • Olivares, Isabel
  • Vera, Mar|||0000-0002-3841-7747
  • Rodriguez, Carmen
  • Del Romero, Jorge
  • López-Galíndez, Cecilio|||0000-0002-2324-9584
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Prado, Julia G.|||0000-0002-5439-4645
  • Pernas, María
Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs. In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC. These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses. The online version contains supplementary material available at 10.1186/s12977-022-00591-7.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Slow progression of pediatric HIV associates with early CD8 + T cell PD-1 expression and a stem-like phenotype

  • Vieira, Vinicius
  • Lim, Nicholas|||0000-0001-9261-7726
  • Singh, Alveera
  • Leitman, Ellen
  • Dsouza, Reena
  • Adland, Emily
  • Muenchhoff, Maximilian|||0000-0001-7016-0470
  • Roider, Julia|||0000-0002-1347-2838
  • Marin Lopez, Miguel
  • Carabelli, Julieta|||0000-0003-2329-3996
  • Giandhari, Jennifer
  • Groll, Andreas|||0000-0001-6787-9118
  • Jooste, Pieter|||0000-0002-8635-2255
  • Prado, Julia G.|||0000-0002-5439-4645
  • Thobakgale, Christina|||0000-0001-5619-8894
  • Dong, Krista|||0000-0002-2038-3518
  • Kiepiela, Photini
  • Prendergast, Andrew J.
  • Tudor-Williams, Gareth|||0000-0002-4488-849X
  • Frater, John|||0000-0001-7163-7277
  • Walker, Bruce D.|||0000-0001-6122-9245
  • Ndung'u, Thumbi|||0000-0003-2962-3992
  • Ramsuran, Veron|||0000-0003-1590-9893
  • Leslie, Alasdair|||0000-0003-2538-6467
  • Kløverpris, Henrik N.|||0000-0002-2165-3313
  • Goulder, Philip|||0000-0002-9842-4674
HIV nonprogression despite persistent viremia is rare among adults who are naive to antiretroviral therapy (ART) but relatively common among ART-naive children. Previous studies indicate that ART-naive pediatric slow progressors (PSPs) adopt immune evasion strategies similar to those described in natural hosts of SIV. However, the mechanisms underlying this immunophenotype are not well understood. In a cohort of early-treated infants who underwent analytical treatment interruption (ATI) after 12 months of ART, expression of PD-1 on CD8 + T cells immediately before ATI was the main predictor of slow progression during ATI. PD-1 + CD8 + T cell frequency was also negatively correlated with CCR5 and HLA-DR expression on CD4 + T cells and predicted stronger HIV-specific T lymphocyte responses. In the CD8 + T cell compartment of PSPs, we identified an enrichment of stem-like TCF-1 + PD-1 + memory cells, whereas pediatric progressors and viremic adults had a terminally exhausted PD-1 + CD39 + population. TCF-1 + PD-1 + expression on CD8 + T cells was associated with higher proliferative activity and stronger Gag-specific effector functionality. These data prompted the hypothesis that the proliferative burst potential of stem-like HIV-specific cytotoxic cells could be exploited in therapeutic strategies to boost the antiviral response and facilitate remission in infants who received early ART with a preserved and nonexhausted T cell compartment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain, the ProHEpiC-19 study

  • Violán, Concepció|||0000-0003-3309-5360
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Lamonja-Vicente, Noemí|||0000-0003-1342-1130
  • Carrasco-Ribelles, Lucía Amalia|||0000-0001-9263-1747
  • Chacón, Carla|||0000-0001-8524-6189
  • Manresa, J.M.|||0000-0001-8306-5798
  • Ramos-Roure, Francesc|||0000-0003-2611-8309
  • Dacosta Aguayo, Rosalia|||0000-0003-1861-365X
  • Palacios-Fernández, Cristina
  • Roso-Llorach, Albert|||0000-0002-9264-0405
  • Pujol, Aleix|||0000-0001-6013-9029
  • Ouchi, Dan|||0000-0002-8630-152X
  • Monteagudo, Mònica|||0000-0002-8839-5056
  • Montero-Alía, Pilar|||0000-0002-9823-1485
  • García-Sierra, Rosa|||0000-0001-9220-610X
  • Arméstar, Fernando|||0000-0002-6374-1418
  • Doladé Botías, María|||0000-0001-8263-3087
  • Prat, Nuria
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Boigues Pons, Marc|||0000-0001-6140-2757
  • Moreno, Nemesio|||0000-0002-1617-9549
  • Prado, Julia G.|||0000-0002-5439-4645
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Understanding the immune response to the SARS-CoV-2 virus is critical for efficient monitoring and control strategies. The ProHEpic-19 cohort provides a fine-grained description of the kinetics of antibodies after SARS-CoV-2 infection with an exceptional resolution over 17 months. We established a cohort of 769 healthcare workers including healthy and infected with SARS-CoV-2 in northern Barcelona to determine the kinetics of the IgM against the nucleocapsid (N) and the IgG against the N and spike (S) of SARS-CoV-2 in infected healthcare workers. The study period was from 5 May 2020 to 11 November 2021.We used non-linear mixed models to investigate the kinetics of IgG and IgM measured at nine time points over 17 months from the date of diagnosis. The model included factors of time, gender, and disease severity (asymptomatic, mild-moderate, severe-critical) to assess their effects and their interactions. 474 of the 769 participants (61.6%) became infected with SARS-CoV-2. Significant effects of gender and disease severity were found for the levels of all three antibodies. Median IgM(N) levels were already below the positivity threshold in patients with asymptomatic and mild-moderate disease at day 270 after the diagnosis, while IgG(N and S) levels remained positive at least until days 450 and 270, respectively. Kinetic modelling showed a general rise in both IgM(N) and IgG(N) levels up to day 30, followed by a decay with a rate depending on disease severity. IgG(S) levels remained relatively constant from day 15 over time. IgM(N) and IgG(N, S) SARS-CoV-2 antibodies showed a heterogeneous kinetics over the 17 months. Only the IgG(S) showed a stable increase, and the levels and the kinetics of antibodies varied according to disease severity. The kinetics of IgM and IgG observed over a year also varied by clinical spectrum can be very useful for public health policies around vaccination criteria in adult population. Regional Ministry of Health of the Generalitat de Catalunya (Call COVID19-PoC SLT16_04; NCT04885478). The online version contains supplementary material available at 10.1186/s12879-022-07696-6.